Atherogenic hyperadrenoreactivity in men with arterial hypertension
Abstract
Aim. То assess the dynamics and interrelations of neuro-humoral and lipid profiles in men with arterial hypertension (AH), based on serum leptin level, adrenoreactivity and lipid profile (ГР) measurement.
Material and methods. The study included 60 AH patients aged 30—60 years: 30 men with Stage I-II AH, risk 1—3, and 30 men with AH and diabetes mellitus (DM). In all participants, body mass index (BMI), serum levels of leptin, total cholesterol (TCH), high, low and very low density lipoprotein CH (HDT, TDT and VTDT-CH) were measured, with atherogenicity coefficient (AC) calculated. Sympatho-adrenal system activity was assessed by beta-adrenoreactivity evaluation (red blood cell osmo-resistance in beta-adrenoblocker test).
Results. In patients with AH and increased BMI, TP changes manifested in increased TCH, TDT-CH, VTDT-CH and AC levels. In DM-free AH individuals, adrenoreactivity directly correlated with atherogenic lipoprotein levels.
Conclusion. In AH patients, atherogenic hyperadrenoreactivity is one of the mechanisms for atherosclerosis development and progression.
About the Authors
S. S. Bunova
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
E. P. Eliseeva
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
V. A. Ostapenko
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
L. P. Firstova
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
M. V. Kolbina
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
А. V. Nelidova
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
P. N. Eliseev
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
L. N. Eliseeva
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
N. A. Nikolaev
Omsk State Medical Academy
Russian Federation
Russian Federation
Faculty Therapy Department
References
1. Балаболкин М.И.,.Дедов И.И. Генетические аспекты сахарного диабета. Сахарныж диабет 2000; 1: 2—10.
2. Оганов Р.Г. Профилактика' сердечно-сосудистых -заболеваний: возможности практического здравоохранения, Кардиоваск тер профил 2002; 1: 5-9.
3. Оганов Р.Г Эпидемиология артериальной гипертонии в России и возможности профилактики. Тер архив 1999; 69(8): 66-9.
4. Стркж Р.И., Длусская И.Г. Ддренореакпгвность и сердечнососудистая система. Москва: Изд-во “Медицина” 2003; 160 с.
5. Чазова И.Е., Мычка В.Б. Метаболический синдром. Москва: Изд-во “Медиа Медика” 2004; 163 с.
6. Шальнова С А., Деев А.Д., Оганов Р.Г. и др. Роль систолического и диастолического артериального давления д ля прогноза смертности от сердечно-сосудистых заболеваний. Кардиоваск тер профил 2002; 1:10-5.
7. Weidmaim Р, Scholm DC, Riesen W, et al. Association between sympathetic activity and the atherogenic serum cholesterol fraction. J Molec Med 1990; 68(5): 269-76.
8. Bjomtorp P. Obesity. Lancet 1997; 350(9075): 423—6.
9. Blum WF, Englaro P, Hanitsch S, et al. Plasma leptiir levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997; 82: 2904-10.
10. Borchard U. The Role of the Sympathetic Nervous System in Cardiovascular Disease. J Clin Basic Cardiol 2001; 4: 175—7.
11. Eikelis N, Lambert G, Wiesner G, et al. Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab 2004; 286(5): 744-52.
12. Kagan BL, Leskin G, Haas B, et al. Elevated lipid levels in Vietnam veterans with chronic posttraumatic stress disorder. Biol Psych 1999; 45(3): 374-7.
13. Felber JP. Insulin and blood pressure in the obesity. Diabetologia 1995; 38(10): 1220-8.
14. Haffner M, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction. N Engl J Med 1998; 339(4): 229-34.
15. Kaimel WB, Cripples LA, Ramaswami R, et al. Regional obesity and risk of cardiovascular disease; the Framingham study. J C-lin Epidemiol 1991; 44(2): 183-90.
16. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
17. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272(3): 205-11.
18. Mark AL, Correia M, Morgan DA, et al. State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the 24 emerging biology of obesity. Hypertension 1999; 33: 537—41.
19. Narkiewicz K, van de Borne PJ, Cooley RL, et al. Sympathetic activity in obese subjects with and without obstructive sleep 25 apnea. Circulation 1998; 98: 772—6.
20. Purdham DM, Zou MX, Rajapurohitam V, et al. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ 26 Physiol 2004; 287: 2877-84.
21. Kaplan JR, Pettersson K, Manuck SB, et al. Role of sympathoadrenal medullary activation in the initiation and progression of 27 atherosclerosis.;Circulation 1991; 84(Suppl 6): 123-32.
22. Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms inhuman obesity-related hypertension. J Hypertens 1999; 17(8): 28 1125-33.
23. Sharma AM. Adipose tissue: a mediator of cardiovascular risk. nt J Obes Relat Metab Disord 2002; 26(Suppl 4): 5—7. Somienberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12(2): 180-6.
24. Pauletto P, Scamiapieco G, Pessina AC. Sympathetic drive and vascular damage in hypertension and atherosclerosis. Hypertension 1991; HlSuppM): III 75-81.
25. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Aim N Y Acad Sci 2006; 1083: 129-52.
26. Trayhurn P, Dunkan JS, Hoggart N, et al. Regulation of leptin production: a dominant role for the sympathetic nervous system? Proc Nutr Soc 1998; 57(3): 413-9. "
27. Vanliala MJ, Kumpusalo EA, Pitkajarvi TK, et al. Metabolic syndrome in a middle-aged Finnish population. J Cardiovase Risk 1997; 4(4): 291-5.
Review
For citations:
Bunova S.S., Eliseeva E.P., Ostapenko V.A., Firstova L.P., Kolbina M.V., Nelidova А.V., Eliseev P.N., Eliseeva L.N., Nikolaev N.A. Atherogenic hyperadrenoreactivity in men with arterial hypertension. Cardiovascular Therapy and Prevention. 2009;8(1):25-30. (In Russ.)
Views:
411
Email this article 
